Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 29, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
Systemic Sclerosis With Lung InvolvementSystemic SclerosisInterstitial Lung Disease
Interventions
DRUG

Mycophenolate Mofetil

"The participant will receive 500 mg to 1000 mg twice daily of mycophenolate mofetil administered orally for 96 weeks.~The dose scheduling will be as follow:~Weeks 1 and 2: 500 mg twice a day Weeks 3 and 4: 750 mg twice a day Weeks 5 to 96: 1000 mg twice a day"

OTHER

Placebo

"The participant will receive 500 mg to 1000 mg twice daily of placebo administered orally for 96 weeks.~The dose scheduling will be as follow:~Weeks 1 and 2: 500 mg twice a day Weeks 3 and 4: 750 mg twice a day Weeks 5 to 96: 1000 mg twice a day"

Trial Locations (3)

H2X 3E4

RECRUITING

Centre hospitalier de l'Université de Montréal (CHUM), Montreal

H3T 1E2

NOT_YET_RECRUITING

Jewish General Hospital - CIUSSS-COMTL, Montreal

Unknown

NOT_YET_RECRUITING

Institut Universitaire de Cardiologie et Pneumologie de Québec, Québec

All Listed Sponsors
collaborator

McGill University

OTHER

collaborator

University of Calgary

OTHER

collaborator

Jewish General Hospital

OTHER

collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Sclérodermie Québec

UNKNOWN

collaborator

Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

OTHER

lead

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER